FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

January 30-31, 2001 Holiday Inn, 8120 Wisconsin Ave., Bethesda, Maryland

AGENDA

Tuesday, January 30

8:00 8:15		Call to Order, Introductions, Administrative Matters Presentation of Plaques to Retiring VRBPAC Members		
8:30		Session 1 – OPEN Session Strain Selection for Influenza Virus Vaccine for the 2001-2002 Season		
	8:30	Introduction and Updates	Dr. Roland Levandowski, FDA Dr. Lance Rodewald, CDC Dr. Wendy Keitel	
	9:50	U.S. Surveillance World Surveillance and Strain Characterization Molecular Characterization of Strains	Dr. Keiji Fukuda, CDC Dr. Nancy Cox, CDC Dr. Alexander Klimov, CDC	
10:30		Break		
	11:00	Additional reports	Ms. Linda Canas, DOD Mr. Alan Hampson Dr. Joanna Ellis	
	12:20	Vaccine Responses Availability of Strains and Reagents Comments from Manufacturers	Dr. Roland Levandowski, FDA Mr. Zhiping Ye, FDA Dr. Slusaw, PhRMA	
12:45		Lunch		
	1:45	Options for Strain Selection	Dr. Nancy Cox, CDC	
1:45		Open Public Hearing		
	2:30	Committee Discussion and Recommendations		
5:00		Adjournment		

FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

January 30-31, 2001 Holiday Inn, 8120 Wisconsin Ave., Bethesda, Maryland

AGENDA

Wednesday, January 31

9 AM		Call to order; introductions; announcements	
9:15		Session 2 — OPEN Session SmithKline Beecham's LYMErix™ Lyme Disease Vacci	ine Safety Update
	9:15	Introduction	Dr. Karen Midthun, FDA
	9:25 9:55	Sponsor's Presentation on Pre-licensure Safety Data Q&A – Clarifications of Sponsor's Presentation	SmithKline Beecham
		FDA Presentation on Pre-licensure Safety Data Q&A – Clarifications of FDA's Presentation	Dr. Patricia Rohan, FDA
10:30		Break	
	11:10	Sponsor's Presentation on Phase 4 Study Sponsor's Presentation on Additional Post-marketing Data Q&A – Clarifications of Sponsor's Presentations	SmithKline Beecham Smith Kline Beecham
		FDA Presentation on Post-licensure Safety Data Q&A – Clarifications of FDA's Presentation	Dr. Robert Ball, FDA
12 noon		Lunch	
1:00		Open Public Hearing	
3:15		Committee Discussion	
5:30		Adjournment	